Strategic focus Target neurology-focused pharma players and contract manufacturers seeking to collaborate on neuroinflammation and neurodegeneration programs, leveraging AZTherapies’ late-stage clinical pipeline in Alzheimer's, ALS, and post-ischemic cognitive impairment to align with partners pursuing CNS disease franchises.

Funding readiness Highlight AGGRESSIVE financings and a substantial capital base (series C-1 and series C) to reassure potential co-development or licensing partners about clinical and regulatory milestones, enabling joint-venture or milestone-driven deals.

Leadership access Engage with a leadership team that includes a former CEO of a major pharma group and a strong scientific advisory board, presenting collaboration opportunities across translational research, CMC, and strategic alliances to accelerate programs.

Science differentiation Position AZTherapies’ multi-modal cromolyn-based approach as a differentiator in neuroinflammation research, opening conversations with companies seeking novel mechanisms to address neurodegenerative disease burden and to expand CNS portfolios.

Operational readiness Capitalize on established manufacturing leadership and CMC capability with experienced executives in manufacturing operations, signaling readiness for co-development manufacturing agreements, tech transfer, and scalable supply for late-stage trials.